Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab
Authors: Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Volume: 27
Issue: 15
ISSN: 0732-183X
Source: Web of Science (Lite)
Preferred by: Tamas Hickish